ArticleJournal of the American Heart Association2026
Impact of Peak Donor Troponin and Donor Troponin Trends on Pediatric Heart Transplant Outcomes.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDonor discard rates for pediatric heart transplant (HT) remain high (≈40%), often driven by concerns about elevated donor troponin levels. This study evaluated the association between peak donor troponin levels, donor troponin trends, and post transplant survival among pediatric HT recipients.
methodsChildren (aged <18 years at listing) who underwent HT between January 2007, and June 2020 were identified from the Organ Procurement and Transplantation Network registry. Recipient and donor characteristics, as well as 1-year post-HT survival, were compared across peak donor troponin I percentiles (0 to <25th, 25th to <75th, ≥75th) and troponin trend categories (increasing, persistently high, persistently low, decreasing).
resultsAmong 4572 donors with reported troponin I values, 67% (n=3097) had abnormal levels. Recipients of donors with peak troponin ≥75th percentile were more frequently aged 11 to 17 years (47.1% versus 22.9% versus 33.1%), had implantable cardioverter-defibrillators (12.8% versus 5.5% versus 8.2%), and exhibited higher creatinine and bilirubin at transplant. Donors with troponin ≥75th percentile were more likely to have undergone cardiopulmonary resuscitation (63.3% versus 44.3% versus 53.7%) and had left ventricular ejection fraction ≤55% (8.7% versus 4.2% versus 6.4%) (
conclusionsMost pediatric HT donors exhibit abnormal troponin levels. Elevated peak donor troponin (>0.66 ng/mL) correlates with donor hemodynamic instability and predicts worse 1-year post transplant graft survival, whereas troponin trajectories are not prognostic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.